Marriage Counselors in Sandy Springs, GA Accepting Medicare
6 Marriage Counselors found. Showing 1 - 6
 Yerina Knoblock, MFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 5887 Glenridge Dr Ste 230, Sandy Springs, GA 30328 Phone: 949-289-1000 |
Lisa R Shankman-price, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 8800 Roswell Rd., Ste. A135, Sandy Springs, GA 30350 Phone: 404-682-1923 |
Rebekka Vatter, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 5883 Glenridge Dr Ste 170, Sandy Springs, GA 30328 Phone: 404-394-1899 |
Kimberly Ruth Sims, MA Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 8800 Roswell Rd Ste A135, Sandy Springs, GA 30350 Phone: 404-737-2670 |
Brenda Saturday, M.A. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 6111 Peachtree Dunwoody Rd Ne, Building F-103, Sandy Springs, GA 30328 Phone: 770-330-2698 |
Dr. Mellonie Hayes Mullins, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 333 Sandy Springs Cir, Suite 103, Sandy Springs, GA 30328 Phone: 404-513-9665 Fax: 770-483-6617 |
News Archive
People with first-episode psychosis may benefit from medication treatment changes, study finds
Many patients with first-episode psychosis receive medications that do not comply with recommended guidelines for first-episode treatment, researchers have found. Current guidelines emphasize low doses of antipsychotic drugs and strategies for minimizing the side effects that might contribute to patients stopping their medication.
Gilenya prevents and reverses symptoms of ventricular hypertrophy
A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.
Researchers identify new culprit that may contribute to heart disease
Medical professionals have long known that the buildup of plaque in arteries can cause them to narrow and harden, potentially leading to a whole host of health problems — including heart attack, heart disease and stroke.
Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).
Using data from wearables to characterize COVID-19 and influenza
By analyzing Fitbit data and self-reported symptoms, researchers from Evidation Health and collaborators analyzed trends in heart rate, step count, and symptom duration between patients with flu and those with COVID-19.
› Verified 3 days ago
Counselors
Pharmacists
Dentists
Clinical Social Workers
Occupational Therapists
Psychologists
Marriage Counselors